Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2018 07:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...